Venus Concept Inc. (VERO): Price and Financial Metrics


Venus Concept Inc. (VERO): $0.76

0.04 (+6.04%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

VERO Stock Summary

  • VERO has a market capitalization of $90,878,642 -- more than approximately only 14.06% of US stocks.
  • VERO's went public 4.47 years ago, making it older than merely 16.65% of listed US stocks we're tracking.
  • In terms of volatility of its share price, VERO is more volatile than 80.96% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Venus Concept Inc, a group of peers worth examining would be TNC, MNTX, ANY, ISDR, and ZCMD.
  • VERO's SEC filings can be seen here. And to visit Venus Concept Inc's official web site, go to www.venusconcept.com.

VERO Valuation Summary

  • In comparison to the median Healthcare stock, VERO's price/sales ratio is 88.55% lower, now standing at 1.3.
  • VERO's price/sales ratio has moved down 12.5 over the prior 47 months.
  • Over the past 47 months, VERO's price/earnings ratio has gone up 9.2.

Below are key valuation metrics over time for VERO.

Stock Date P/S P/B P/E EV/EBIT
VERO 2021-08-31 1.3 3.2 -4.0 -7.8
VERO 2021-08-30 1.3 3.1 -3.9 -7.7
VERO 2021-08-27 1.3 3.1 -3.9 -7.7
VERO 2021-08-26 1.2 2.9 -3.7 -7.3
VERO 2021-08-25 1.2 3.0 -3.8 -7.5
VERO 2021-08-24 1.2 2.9 -3.7 -7.3

VERO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VERO has a Quality Grade of C, ranking ahead of 56.31% of graded US stocks.
  • VERO's asset turnover comes in at 0.629 -- ranking 64th of 186 Medical Equipment stocks.
  • 500 - Internal server error

The table below shows VERO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.629 0.676 -0.148
2021-03-31 0.567 0.666 -0.233
2020-12-31 0.508 0.659 -0.503
2020-09-30 0.937 0.703 -0.500
2020-06-30 1.031 0.701 -0.667
2020-03-31 1.225 0.694 -0.875

VERO Price Target

For more insight on analysts targets of VERO, see our VERO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.55 Average Broker Recommendation 1.3 (Strong Buy)

VERO Stock Price Chart Interactive Chart >

Price chart for VERO

VERO Price/Volume Stats

Current price $0.76 52-week high $3.37
Prev. close $0.72 52-week low $0.62
Day low $0.68 Volume 225,874
Day high $0.80 Avg. volume 214,497
50-day MA $1.08 Dividend yield N/A
200-day MA $1.62 Market Cap 48.88M

Venus Concept Inc. (VERO) Company Bio


Venus Concept Inc. (formerly Restoration Robotics, Inc.), a medical device company, develops and commercializes image-guided robotic systems in the United States and internationally. It offers ARTAS System, a physician-assisted robotic system that identifies and dissects hair follicular units directly from the scalp and creates recipient implant sites. The company was founded in 2002 and is based in San Jose, California.


VERO Latest News Stream


Event/Time News Detail
Loading, please wait...

VERO Latest Social Stream


Loading social stream, please wait...

View Full VERO Social Stream

Latest VERO News From Around the Web

Below are the latest news stories about Venus Concept Inc that investors may wish to consider to help them evaluate VERO as an investment opportunity.

Analysts Expect Breakeven For Venus Concept Inc. (NASDAQ:VERO) Before Long

Venus Concept Inc. ( NASDAQ:VERO ) is possibly approaching a major achievement in its business, so we would like to...

Yahoo | February 9, 2022

Venus Concept Inc. to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16th

TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that management will participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Management will participate in a virtual fireside chat at the conference on Wednesday, February 16th at 11:00 a.m. Eastern Time. A webcast of the fireside chat will be available to BTIG clients attending

Yahoo | February 8, 2022

Venus Concept to Release Fourth Quarter and Fiscal Year 2021 Financial Results on March 28, 2022

TORONTO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that fourth quarter and fiscal year 2022 financial results will be released before the market opens on Monday, March 28, 2022. Management will host a conference call at 8:00 a.m. Eastern Time on March 28, 2022 to discuss the results of the quarter and fiscal year with a question and answer session. Those who would like to p

Yahoo | February 2, 2022

Venus Concept gets FDA nod to market BlissMAX device

Venus Concept (VERO) has won FDA 510(k) clearance to market its Venus BlissMAX device in the U.S.BlissMAX is a medical aesthetic platform that serves as a comprehensive solution for

Seeking Alpha | January 19, 2022

BTIG Remains a Buy on Venus Concept (VERO)

In a report released today, Marie Thibault from BTIG reiterated a Buy rating on Venus Concept (VERO – Research Report), with a price target of $7.00. The company's shares closed last Tuesday at $1.73. According to TipRanks.com, Thibault is a 5-star analyst with an average return of 26.5% and a 39.6% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Edwards Lifesciences, and Irhythm Technologies. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Venus Concept with a $5.00 average price target.

Christine Brown on TipRanks | January 18, 2022

Read More 'VERO' Stories Here

VERO Price Returns

1-mo -23.07%
3-mo -51.90%
6-mo -44.53%
1-year -63.46%
3-year -99.42%
5-year N/A
YTD -55.29%
2021 -1.73%
2020 -63.19%
2019 -95.25%
2018 -90.43%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5846 seconds.